Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Pressure Grows To Solve Northern Ireland Supply Issues

BGMA Calls For Urgent UK-EU Agreement To Resolve Regulatory Uncertainty

Executive Summary

As political tensions between the UK and EU mount over the Northern Ireland Protocol instigated as part of the pair’s Brexit agreement, the off-patent industry is growing increasingly concerned that regulatory uncertainty will put supply at risk.

You may also be interested in...



EU To Offer Solution To Post-Brexit Regulatory Problems In Northern Ireland

The EU is preparing a formal proposal for ensuring the continued long-term supply of medicines from Great Britain to Northern Ireland from next year, but it will require "enhanced enforcement" by the UK authorities.

Alvotech And Stada Gain Second Ever Higher-Strength Adalimumab Nod

Alvotech and Stada are on the verge of gaining the world’s second ever approval for a higher-strength Humira biosimilar, after the EMA’s CHMP endorsed the firms’ adalimumab under the names Hukyndra and Libmyris at its September meeting.

EU’s Health Emergency Response Plans Must Address Existing Flaws

The EU’s creation of a Health Emergency Response Authority to deal with future health threats has been welcomed by off-patent industry association Medicines for Europe. However, the organization pointed out current policy and regulatory weaknesses that must be addressed if HERA is to be successful.

Topics

UsernamePublicRestriction

Register

GB151117

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel